- Home
- SKY vs RVPHW Comparison
SKY vs RVPHW Comparison
Compare SKY & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKY
- RVPHW
- Stock Information
- Founded
- SKY 2010
- RVPHW N/A
- Country
- SKY United States
- RVPHW United States
- Employees
- SKY N/A
- RVPHW 15
- Industry
- SKY Homebuilding
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- SKY Consumer Discretionary
- RVPHW Health Care
- Exchange
- SKY Nasdaq
- RVPHW Nasdaq
- Market Cap
- SKY N/A
- RVPHW N/A
- IPO Year
- SKY N/A
- RVPHW 2018
- Fundamental
- Price
- SKY $97.16
- RVPHW $0.19
- Analyst Decision
- SKY Hold
- RVPHW
- Analyst Count
- SKY 5
- RVPHW 0
- Target Price
- SKY $85.40
- RVPHW N/A
- AVG Volume (30 Days)
- SKY 406.3K
- RVPHW N/A
- Earning Date
- SKY 10-28-2024
- RVPHW N/A
- Dividend Yield
- SKY N/A
- RVPHW N/A
- EPS Growth
- SKY N/A
- RVPHW N/A
- EPS
- SKY 2.58
- RVPHW N/A
- Revenue
- SKY $2,340,474,000.00
- RVPHW N/A
- Revenue This Year
- SKY $21.00
- RVPHW N/A
- Revenue Next Year
- SKY $7.18
- RVPHW N/A
- P/E Ratio
- SKY $37.57
- RVPHW N/A
- Revenue Growth
- SKY 16.86
- RVPHW N/A
- 52 Week Low
- SKY $58.35
- RVPHW N/A
- 52 Week High
- SKY $101.39
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- SKY 59.72
- RVPHW N/A
- Support Level
- SKY $93.79
- RVPHW N/A
- Resistance Level
- SKY $98.87
- RVPHW N/A
- Average True Range (ATR)
- SKY 3.06
- RVPHW 0.00
- MACD
- SKY 0.65
- RVPHW 0.00
- Stochastic Oscillator
- SKY 86.97
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.